

ED	ED
EP	EP
EEV	ED
EA	EA

6/1/20
 6/1/20
 6/1/20
 6/1/20

6/1/20



- a) Inadequate response to at least one preferred disease-modifying MS drug
- b) Highly active disease (aggressive or rapidly evolving) in the expert opinion of the prescriber; AND
- 5. Member has tested negative for active hepatitis B, or a hepatologist has been consulted; AND
- 6. 300.001 T0 (s)-1.6gCID 12 t(ber)0.r0.009ehno.5 reW nID 12 t5 ()TjEMC /o 10eh3n,BDCId-1.153 Ta 1o374 59



- Implementation Subcommittee of the American Academy of Neurology [published correction appears in *Neurology*. 2019 Jan 8;92(2):112]. . 2018;90(17):777-788
8. National Multiple Sclerosis Society. The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence. A Consensus Paper by the Multiple Sclerosis Coalition; 2019. Available from: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf. Accessed August 18, 2021.
 9. Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. . 2022;5(5):CD013247. Published 2022 May 18. doi:10.1002/14651858.CD013247.pub2
 10. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. ;133(12):1380-1390.e2. doi:10.1016/j.amjmed.2020.05.049
 11. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review [published correction appears in *JAMA*. 2021 Jun 1;325(21):2211]. . 2021;325(8):765-779. doi:10.1001/jama.2020.26858

Effective date: 01/01/2023

Revised date: 07/14/2022